Abstracts tagged "non-radiographic"

Abstract Number: 623 • 2019 ACR/ARP Annual Meeting
Evaluation of the Early Cervical Structural Changes in Patients with Non-Radiographic Axial Spondyloarthropathy
Melike Cengiz ¹, Şebnem Ataman², Ayşe Peyman Yalçın ³, Ismihan Sunar ³ and Gürkan Yılmaz ³, ¹Ankara Unversity School of Medicine, Physical Medicine and Rehabilitation Department, Ankara, Ankara, Turkey, ²Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Ankara, Turkey, ³Ankara Unversity School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Turkey
Background/Purpose: The aim of this double-blind, controlled, cross-sectional study is to compare the cervical vertebral structural changes of the patients with nr-axSpA, AS and control…
Abstract Number: 626 • 2019 ACR/ARP Annual Meeting
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Marco Garrido-Cumbrera¹, Jordi Gratacós ², Eduardo Collantes ³, Pedro Zarco ⁴, Carlos Sastre ⁵, Sergio Sanz-Gómez ⁶ and Victoria Navarro-Compán ⁷, ¹Health & Territory Research, Universidad de Sevilla, Seville, Spain, Sevilla, ²Hospital Universitari Parc Taulí, Sabadell, I3PT, UAB, Spain, Sabadell, Spain, ³Reina Sofia University Hospital, Spain. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain, Cordova, Spain, ⁴Hospital Universitario Fundación Alcorcón, Madrid, Spain, Madrid, Spain, ⁵Novartis Spain, Barcelona, Spain, Barcelona, Spain, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, ⁷University Hospital La Paz, IdiPaz, Madrid, Spain
Background/Purpose: Most research studies support the fact that both, radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA), share similar clinical characteristics and equivalent burden of…
Abstract Number: 1507 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Atul Deodhar¹, Lianne Gensler ², Jonathan Kay ³, Walter P. Maksymowych ⁴, Nigil Haroon ⁵, Robert B.M. Landewé ⁶, Martin Rudwaleit ⁷, Stephen Hall ⁸, Lars Bauer ⁹, Bengt Hoepken ⁹, Natasha de Peyrecave ¹⁰, Thomas Kumke ¹¹ and Désirée van der Heijde ¹², ¹Oregon Health & Science University, Portland, OR, ²University San Francisco California, San Francisco, CA, ³UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁴University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁵Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁸Monash University and Emeritus Research, Melbourne, Australia, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹UCB Pharma, Monheim, Germany, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to…
Abstract Number: 1508 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Lianne Gensler ¹, Jonathan Kay ², Walter P. Maksymowych ³, Nigil Haroon ⁴, Lars Bauer ⁵, Bengt Hoepken ⁵, Natasha de Peyrecave ⁶, Thomas Kumke ⁷ and Atul Deodhar⁸, ¹University San Francisco California, San Francisco, CA, ²UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Pain, fatigue, morning stiffness and impaired sleep are some of the main symptoms contributing to reduced quality of life (QoL) in patients (pts) with…
Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…
Abstract Number: 2729 • 2019 ACR/ARP Annual Meeting
Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Atul Deodhar¹, Désirée van der Heijde ², Lianne Gensler ³, Tae-Hwan Kim ⁴, Walter P. Maksymowych ⁵, Mikkel Østergaard ⁶, Denis Poddubnyy ⁷, Helena Marzo-Ortega ⁸, Louis Bessette ⁹, Tetsuya Tomita ¹⁰, Gaia Gallo ¹¹, David Adams ¹¹, Ann Leung ¹², Fangyi Zhao ¹¹, Maja Hojnik ¹¹, Hilde Carlier ¹³ and Joachim Sieper ¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³University San Francisco California, San Francisco, CA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁸NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ⁹Laval University, Quebec City, QC, Canada, ¹⁰Osaka University Graduate School of Medicine, Osaka, Japan, ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Syneos Health, Raleigh, NC, ¹³Eli Lilly and Company, Indianapolis, ¹⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Ixekizumab (IXE), a high affinity IL-17A monoclonal antibody, previously showed efficacy in AS/radiographic-axSpA1,2. COAST-X (NCT02757352) is a phase 3 study that assessed efficacy and…
Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Atul A. Deodhar¹, Lianne S. Gensler², Jonathan Kay³, Walter P. Maksymowych⁴, Nigil Haroon⁵, Robert B.M. Landewé⁶, Martin Rudwaleit⁷, Stephen Hall⁸, Lars Bauer⁹, Bengt Hoepken⁹, Natasha de Peyrecave¹⁰, Brian Kilgallen¹¹ and Désirée van der Heijde¹², ¹Oregon Health and Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, ⁸Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
Abstract Number: 2581 • 2018 ACR/ARHP Annual Meeting
Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Theresa Hunter¹, David Sandoval Calderon¹, Steve Lobosco², Rachel Moon², Gary Milligan³ and Rebecca Bolce¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Adelphi Real World, Macclesfield, United Kingdom, ³Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: To compare TNF inhibitor (TNFi) use and switching patterns among patients with nr-axSpA in the United States (US) and Europe (EU). Methods: Data from…
Abstract Number: 1519 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study
Carlos M Gonzalez¹, Rosa Expósito², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷, Manuel Fernández⁸ and Mercedes Morcillo⁹, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain, ⁹Rheumatology, Hospital El Escorial, San Lorenzo de el Escorial, Spain
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. RAPID-axSpA trial investigated the efficacy and…
Abstract Number: 2511 • 2017 ACR/ARHP Annual Meeting
Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?
Tor Olofsson¹, Elisabeth Mogard¹, Jan Marsal², Mats Geijer³, Lars Erik Kristensen⁴, Elisabet Lindqvist¹ and Johan K Wallman⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences Lund, Gastroenterology, Lund University, Lund, Sweden, ³Department of Radiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ⁴Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁵Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden
Background/Purpose: While inflammatory bowel disease (IBD) is a well-known comorbidity in axial spondyloarthritis (SpA), little is known about functional bowel problems, such as irritable bowel…
Abstract Number: 2842 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Justine Corli¹, Rene-Marc Flipo¹, Peggy Philippe², Anne Bera-Louville², Cecile Wibaux² and Julien Paccou², ¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ²Hopital R Salengro CHRU, Lille, France
Background/Purpose: Several studies have demonstrated that Tumor Necrosis Factor Inhibitors (TNFi) are efficient in non-radiographic axial spondyloarthritis (Nr-AxSpA). However, few investigations have directly compared ankylosing…
Abstract Number: 2854 • 2015 ACR/ARHP Annual Meeting
Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Désirée van der Heijde¹, Maxime Dougados², Walter Maksymowych³, Gina Bergman⁴, Sean P. Curtis⁴, Anjela Tzontcheva⁴, George Philip⁴, Susan Huyck⁴ and Joachim Sieper⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Paris-Descartes University, Paris, France, ³University of Alberta, Edmonton, AB, Canada, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: The tolerability and efficacy of golimumab (GLM) as a treatment for nonradiographic axial spondyloarthritis (nr-axSpA) were recently investigated in a randomized, double-blind (DB), placebo…
Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Maxime Dougados¹, Gina Bergman², Walter Maksymowych³, Sean P. Curtis², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Paris-Descartes University, Paris, France, ²Merck & Co., Inc., Kenilworth, NJ, ³University of Alberta, Edmonton, AB, Canada, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…
Abstract Number: 2893 • 2015 ACR/ARHP Annual Meeting
Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Walter Maksymowych¹, Sean P. Curtis², Maxime Dougados³, Gina Bergman², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ, ³Paris-Descartes University, Paris, France, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Chronic inflammation, back pain, and progressive spinal stiffness associated with axial spondyloarthritis (axSpA) can decrease quality of life (QoL). The purpose of this study…
Abstract Number: 2594 • 2014 ACR/ARHP Annual Meeting
Differences in Localization and Activity of the Entheseal Involvement Between Non-Radiographic and Radiographic Axial Spondyloarthritis By the Ultrasound Assessment
Marketa Fojtikova¹, Karel Pavelka¹, Sarka Forejtova² and Jindra Gatterova³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ³Institute of rheumatology, Prague 2, Czech Republic
Background/Purpose Inflammatory involvement of peripheral enthesis belongs to an important sign of spondyloarthritis (SpA). It may occur in patients with long-term as well as newly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].